Diligence memo · auto-generated · as of July 2, 2026
GreenMark Biomedical Inc.
GreenMark Biomedical Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
GreenMark Biomedical Inc. operates in Biotechnology, based in EAST LANSING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
GreenMark Biomedical Inc. has raised $4.2M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2020-07-17.
Most recent recorded round closed around 2025-01-21.
Valuation (modeled)modeled
Provath models GreenMark Biomedical Inc. at approximately $1.8M (range $360K–$4.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.39× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 40% of Biotechnology peers (4293 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.